Ivabradine Shows Promise as Tx for Hyperadrenergic POTS

Further study needed in other POTS subtypes In patients with hyperadrenergic postural orthostatic tachycardia syndrome (POTS), one month of treatment with ivabradine brought about significant improvements in several parameters, including heart rate, quality of life (QOL), and plasma norepinephrine (NE) levels, according to results from a recent study published in the Journal of the American

PDF) Ivabradine in Postural Orthostatic Tachycardia Syndrome: A

Acute hyperhidrosis and postural tachycardia in a COVID-19 patient

PDF) Age-dependent modulation of xenobiotic metabolism in primary

Ivabradine effects on COVID-19-associated postural orthostatic

Summary of treatment options existing for POTS with the

Ivabradine Shows Promise as Tx for Hyperadrenergic POTS - Physician's Weekly

Cardiac Origins of the Postural Orthostatic Tachycardia Syndrome

PDF) 2015 Heart Rhythm Society Expert Consensus Statement on the

Frontiers Chronic Treatment with Ivabradine Does Not Affect

Potential role of Ivabradine in children with Long Covid and a

Cureus Choices and Challenges With Drug Therapy in Postural

PDF) Age-dependent modulation of xenobiotic metabolism in primary